# Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

> **NCT01814865** · PHASE2 · WITHDRAWN · sponsor: **British Columbia Cancer Agency**

## Conditions studied

- Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** Aromatase Inhibitor

## Key facts

- **NCT ID:** NCT01814865
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-05
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding was not acquired
- **Last updated:** 2013-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814865, "Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01814865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*